Literature DB >> 2973147

Organization of dopamine D1 and D2 receptors in human striatum: receptor autoradiographic studies in Huntington's disease and schizophrenia.

J N Joyce1, N Lexow, E Bird, A Winokur.   

Abstract

The technique of quantitative autoradiography was used to examine the effects of Huntington's disease (HD) and schizophrenia on the organization of striatal dopamine (DA) D1 and D2 receptors. Whereas the striatum of HD cases showed a reduction in the density of D1 ([3H]SCH 23390) and D2 ([3H]spiroperidol) receptors, the patterning of D2 receptor loss did not match that of the D1 receptor loss. The HD loss of D1 D1 receptors (65%) is far greater than the loss of D2 receptors (28%). Whereas there was a dorsal-ventral gradient of effect on both receptor subtypes, the effects of HD on D2 receptors in the ventral putamen (PUT) and nucleus accumben septi (NAS) were minimal. Similarly, muscarinic M1 and M2 receptors demonstrate different patterns of alteration in HD. The M2 subtype, labeled with [3H]N-methylscopolamine (in the presence of excess pirenzepine to occlude M1 sites), was depleted far more than the M1 receptor subtype, labeled with [3H]pirenzepine. Although the effects of HD on [3H]mazindol labeling of DA terminals were more heterogeneous, there appeared to be a relative preservation of this afferent input to the striatum of the HD cases. In the schizophrenic cases, our autoradiographic studies confirm previous reports of an elevation of D2 receptor density in the striata of many schizophrenics. This increase was evident even though two of the three cases were known to have not been treated with neuroleptics, and the third case may also have been drug naive. However, the increase was far greater in the NAS (164%) and ventral PUT (173%) than more dorsally in the striatum (68%). The density of D1 receptors and DA terminals labeled with [3H]mazindol in the striatum of schizophrenics was not significantly different from that of control cases. Thus in both HD and schizophrenia, the ratio of D2/D1 receptors is altered in favor of the D2 population, particularly in the NAS.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2973147     DOI: 10.1002/syn.890020511

Source DB:  PubMed          Journal:  Synapse        ISSN: 0887-4476            Impact factor:   2.562


  32 in total

Review 1.  Aspects of PET imaging relevant to the assessment of striatal transplantation in Huntington's disease.

Authors:  L Besret; A L Kendall; S B Dunnett
Journal:  J Anat       Date:  2000-05       Impact factor: 2.610

2.  Prefrontal dopamine D1 receptors and working memory in schizophrenia.

Authors:  Anissa Abi-Dargham; Osama Mawlawi; Ilise Lombardo; Roberto Gil; Diana Martinez; Yiyun Huang; Dah-Ren Hwang; John Keilp; Lisa Kochan; Ronald Van Heertum; Jack M Gorman; Marc Laruelle
Journal:  J Neurosci       Date:  2002-05-01       Impact factor: 6.167

3.  Receptor alterations in manganese intoxicated monkeys.

Authors:  H Eriksson; P G Gillberg; S M Aquilonius; K G Hedström; E Heilbronn
Journal:  Arch Toxicol       Date:  1992       Impact factor: 5.153

Review 4.  Using human brain imaging studies as a guide toward animal models of schizophrenia.

Authors:  S S Bolkan; F Carvalho Poyraz; C Kellendonk
Journal:  Neuroscience       Date:  2015-05-30       Impact factor: 3.590

5.  Measurement of density and affinity for dopamine D(2) receptors by a single positron emission tomography scan with multiple injections of [(11)C]raclopride.

Authors:  Yoko Ikoma; Hiroshi Watabe; Takuya Hayashi; Yoshinori Miyake; Noboru Teramoto; Kotaro Minato; Hidehiro Iida
Journal:  J Cereb Blood Flow Metab       Date:  2009-11-11       Impact factor: 6.200

6.  Tetrabenazine is neuroprotective in Huntington's disease mice.

Authors:  Hongyu Wang; Xi Chen; Yuemei Li; Tie-Shan Tang; Ilya Bezprozvanny
Journal:  Mol Neurodegener       Date:  2010-04-26       Impact factor: 14.195

7.  Dopamine D1 receptor number--a sensitive PET marker for early brain degeneration in Huntington's disease.

Authors:  G Sedvall; P Karlsson; A Lundin; M Anvret; T Suhara; C Halldin; L Farde
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1994       Impact factor: 5.270

8.  Corticostriatal dysfunction underlies diminished striatal ascorbate release in the R6/2 mouse model of Huntington's disease.

Authors:  Jenelle L Dorner; Benjamin R Miller; Emma L Klein; Alexander Murphy-Nakhnikian; Rachel L Andrews; Scott J Barton; George V Rebec
Journal:  Brain Res       Date:  2009-07-16       Impact factor: 3.252

9.  Prenatal protein deprivation alters dopamine-mediated behaviors and dopaminergic and glutamatergic receptor binding.

Authors:  Abraham A Palmer; Alan S Brown; Debbra Keegan; Lara DeSanti Siska; Ezra Susser; John Rotrosen; Pamela D Butler
Journal:  Brain Res       Date:  2008-07-30       Impact factor: 3.252

10.  Selective D1- and D2-dopamine receptor blockade both induces akathisia in humans--a PET study with [11C]SCH 23390 and [11C]raclopride.

Authors:  L Farde
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.